Company profile for Kezar Life Sciences

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Founded in 2015 and based in South San Francisco, we are a clinical-stage biotechnology company committed to revolutionizing treatments for patients with autoimmune diseases and cancer. We are translating our innovative research on the immunoproteasome and protein secretion pathways to advance novel therapeutic approaches. KZR-616, a first-in-class immunoproteasome inhibitor, is currently in three Phase 2 trials across five se...
Founded in 2015 and based in South San Francisco, we are a clinical-stage biotechnology company committed to revolutionizing treatments for patients with autoimmune diseases and cancer. We are translating our innovative research on the immunoproteasome and protein secretion pathways to advance novel therapeutic approaches. KZR-616, a first-in-class immunoproteasome inhibitor, is currently in three Phase 2 trials across five separate autoimmune diseases of high unmet need - lupus nephritis, dermatomyositis/polymyositis, and autoimmune hemolytic anemia/immune thrombocytopenia.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
4000 Shoreline Court, Suite 300, South San Francisco, CA 94080
Telephone
Telephone
(650) 822-5600
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251112668726/en/Kezar-Life-Sciences-Reports-Third-Quarter-2025-Financial-Results

BUSINESSWIRE
12 Nov 2025

https://www.biospace.com/business/kezar-loses-70-of-staff-after-fda-cancels-meeting-on-autoimmune-asset

BIOSPACE
10 Nov 2025

https://www.businesswire.com/news/home/20251107342037/en/Kezar-Life-Sciences-Announces-Presentation-of-PORTOLA-Data-at-the-American-Association-for-the-Study-of-Liver-Disease-AASLD-The-Liver-Meeting-2025

BUSINESSWIRE
07 Nov 2025

https://www.fiercebiotech.com/biotech/kezar-plans-layoffs-after-fda-cancels-meeting-discuss-next-trial

FIERCE BIOTECH
17 Oct 2025

https://www.pharmiweb.com/press-release/2025-10-16/kezar-life-sciences-announces-regulatory-update-on-zetomipzomib-program-in-autoimmune-hepatitis-and

PHARMIWEB
16 Oct 2025

https://www.businesswire.com/news/home/20250828473829/en/Kezar-Life-Sciences-to-Participate-in-Two-Upcoming-Investor-Conferences

BUSINESSWIRE
28 Aug 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty